Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, B-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, China National Postdoctoral Program for Innovative Talents.
Abstract (Originalsprache)
While cancer immunotherapy has traditionally centered on T cells, accumulating evidence highlights the dual roles of tumor-infiltrating B lymphocytes (TIL-Bs) in both promoting and restraining tumor progression. Within tertiary lymphoid structures (TLSs), TIL-Bs undergo germinal center (GC) maturation and generate tumor-reactive antibodies that enhance antitumor T-cell immunity. However, in defined spatial, inflammatory, or cytokine-rich niches, B cells can acquire immunosuppressive phenotypes, including interleukin (IL)-10 + , IL-35 + , TGF-β + , programmed cell death protein 1/programmed death-ligand 1 + subsets and IgA + plasma cells. These populations suppress cytotoxic CD4 + /CD8 + T cells, expand regulatory T cells, and impair dendritic cell function, thereby establishing an immunosuppressive tumor microenvironment. TIL-Bs also contribute to chronic inflammation, complement activation, and angiogenesis through polyclonal activation and immune complex formation. Tumor-infiltrating antibodies, particularly IgA, demonstrate context-dependent effects that are shaped by antigen specificity, isotype, and Fc-mediated interactions. Importantly, immunoregulatory B-cell subsets are increasingly implicated in resistance to immune checkpoint blockade and chemotherapy. This review synthesizes emerging insights into the tumor-promoting roles of TIL-Bs, emphasizing their spatially regulated phenotypic plasticity and immunosuppressive mechanisms, and highlights strategies to selectively target pathogenic B-cell subsets while preserving antitumor functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, China.
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China yinghan@csu.edu.cn vccj07@csu.edu.cn.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- China National Postdoctoral Program for Innovative Talents
- the Graduate Research Innovation Project of Central South University
- National Key R&D Program of China for Major Chronic Diseases
- Hunan Provincial Natural Science Foundation
Zitieren
APA
Gao, Y., Peng, Y., Chen, Y., Zeng, S., Shen, H., Martin, A., Cai, C., & Han, Y. (2026). Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014745
Vancouver
Gao Y, Peng Y, Chen Y, Zeng S, Shen H, Martin A, et al. Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014745
BibTeX
@article{Gao2026,
author = {Gao, Yan and Peng, Yinghui and Chen, Yihong and Zeng, Shan and Shen, Hong and Martin, Alberto and Cai, Changjing and Han, Ying},
title = {Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014745}
}
EUVIMED